ASH 2020 | Decitabine plus venetoclax is comparable to intensive chemotherapy in R/R AML
Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results from a comparison of 10-day decitabine plus venetoclax therapy (DEC10-VEN) and intensive chemotherapy (IC) in relapsed/refractory acute myeloid leukemia (AML), a cohort lacking standard approved treatments. A propensity score-matched analysis (PSMA) analysis was conducted to match DEC10-VEN patients with IC patients, based on age, ELN risk group, ECOG performance status, and number of prior therapies. The results show DEC10-VEN has efficacy as salvage therapy, comparable to intensive chemotherapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultancy (includes expert testimony): AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji
Equity ownership: Stocks, Reata Pharmaceuticals
Research funding: AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, Astra Zeneca
Patents and royalties: Reata Pharmaceuticals
